{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-057577","form_type":"8-K","ticker":"CBDY","cik":"0001586554","company_name":"Target Group Inc.","filed_at":"2022-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.330459+00:00","generated_at":"2026-06-25T22:24:52.143013+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Target Group subsidiary receives CDN$2.04M payout from Thrive, JV continues","bullets":["CanaryRx (Target Group subsidiary) received CDN$2,043,082.74 from Thrive to fully repay JV indebtedness.","Thrive paid the amount on May 6, 2022, satisfying all Outstanding JV and Product Obligations.","The Joint Venture Operations Agreement between CanaryRx, Thrive, and JVCo remains in full force.","The payout covers start-up hard costs ($921,581.48) and excess costs ($1,121,501.26).","The agreement facilitates Thrive's parent Terrafarma's planned amalgamation with Aurora Cannabis Inc."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-057577","json":"https://secwatch.observer/filing/0001104659-22-057577.json","markdown":"https://secwatch.observer/filing/0001104659-22-057577.md","text":"https://secwatch.observer/filing/0001104659-22-057577.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1586554/000110465922057577/0001104659-22-057577-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1586554/000110465922057577/tm2214947d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T22:24:52.143013+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}